Effects of Tafamidis on Left Ventricular Strain in Patients With Wild-Type Transthyretin Cardiac Amyloidosis With and Without Diabetes Mellitus

Kojiro Tsurukawa; Hiroaki Kawano; Chisa Eguchi; Rosy Haruna Nishizawa; Tsuyoshi Yoshimuta; Kentaro Furukawa; Takako Minami; Masamichi Eguchi; Satoshi Ikeda; Koji Maemura

doi:10.1253/circrep.CR-26-0232

Research Letters

Effects of Tafamidis on Left Ventricular Strain in Patients With Wild-Type Transthyretin Cardiac Amyloidosis With and Without Diabetes Mellitus

Kojiro Tsurukawa, Hiroaki Kawano , Chisa Eguchi, Rosy Haruna Nishizawa, Tsuyoshi Yoshimuta, Kentaro Furukawa, Takako Minami, Masamichi Eguchi, Satoshi Ikeda, Koji Maemura

Author information

Keywords: Amyloidosis, Cardiac function, Treatment

JOURNAL OPEN ACCESS FULL-TEXT HTML

2026 Volume 8 Issue 10 Pages 1761-1764

DOI https://doi.org/10.1253/circrep.CR-26-0232

Browse “Advance online publication” version

Details

Abstract

Background: Tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), but the effect of diabetes mellitus (DM) on the efficacy of tafamidis is unknown.

Methods and Results: We included 57 patients (median age, 77 years) with ATTRwt-CA to compare global longitudinal strain (GLS) before and 1 year after treatment with tafamidis in patients with and without DM (Non-DM, 43 patients; DM, 14 patients). GLS was only ameliorated in patients without DM.

Conclusions: The change in GLS at 1 year after tafamidis treatment may be different in ATTRwt-CM patients with and without DM.

Fullsize Image

Corresponding author

Register with J-STAGE for free!